EGFR-TKI Combined with Pemetrexed Versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2023 Feb 15

PMID 36791768

Authors

Weiguang Gu

Hua Zhang

Yiyu Lu

Minjing Li

Shuang Yang

Jianmiao Liang

Zhijian Ye

Zhihua Li

Minhong He

Xiaoliang Shi

Fei Wang

Dong You

Weiquan Gu

Weineng Feng

Affiliations

Soon will be listed here.

Abstract

Purpose: We aimed to evaluate whether the addition of pemetrexed is effective in improving progression-free survival (PFS) in epidermal growth factor receptor (EGFR)-mutated patients with or without concomitant alterations.

Materials And Methods: This multicenter clinical trial was conducted in China from June 15, 2018, to May 31, 2019. A total of 92 non-small cell lung cancer (NSCLC) patients harboring EGFR-sensitive mutations were included and divided into concomitant and non-concomitant groups. Patients in each group were randomly treated with EGFR-tyrosine kinase inhibitor (TKI) monotherapy or EGFR-TKI combined with pemetrexed in a ratio of 1:1. PFS was recorded as the primary endpoint.

Results: The overall median PFS of this cohort was 10.1 months. There were no significant differences in PFS between patients with and without concomitant and between patients received TKI monotherapy and TKI combined with pemetrexed (p=0.210 and p=0.085, respectively). Stratification analysis indicated that patients received TKI monotherapy had a significantly longer PFS in non-concomitant group than that in concomitant group (p=0.002). In concomitant group, patients received TKI combined with pemetrexed had a significantly longer PFS than patients received TKI monotherapy (p=0.013). Molecular dynamic analysis showed rapidly emerging EGFR T790M in patients received TKI monotherapy. EGFR mutation abundance decreased in patients received TKI combined chemotherapy, which supports better efficacy for a TKI combined chemotherapy as compared to TKI monotherapy. A good correlation between therapeutic efficacy and a change in circulating tumor DNA (ctDNA) status was found in 66% of patients, supporting the guiding role of ctDNA minimal residual disease (MRD) in NSCLC treatment.

Conclusion: EGFR-TKI monotherapy is applicable to EGFR-sensitive patients without concomitant alterations, while a TKI combined chemotherapy is applicable to EGFR-sensitive patients with concomitant alterations. CtDNA MRD may be a potential biomarker for predicting therapeutic efficacy.

Citing Articles

Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs.

Kuang L, Zhang Y, Wang H, Wang P, Li Y BMC Pulm Med. 2025; 25(1):114.

PMID: 40082918 PMC: 11907820. DOI: 10.1186/s12890-025-03569-1.

Strategies and influencing factors for the treatment of advanced non-small cell lung cancer based on epidermal growth factor receptor tyrosine kinase inhibitors: a narrative review.

Kuang L, Wang P, Zhou L, Li Y Transl Cancer Res. 2024; 13(9):5123-5140.

PMID: 39430833 PMC: 11483425. DOI: 10.21037/tcr-24-637.

Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review.

Restrepo J, Martinez Guevara D, Pareja Lopez A, Montenegro Palacios J, Liscano Y Cancers (Basel). 2024; 16(13).

PMID: 39001401 PMC: 11240412. DOI: 10.3390/cancers16132338.

SP3-induced Timeless transcription contributes to cell growth of lung adenocarcinoma cells.

Tian P, Du D, Yang L, Zhou N, Tao L PLoS One. 2024; 19(2):e0298295.

PMID: 38354174 PMC: 10866488. DOI: 10.1371/journal.pone.0298295.

References

Li X, Cai W, Yang G, Su C, Ren S, Zhao C . Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. J Thorac Oncol. 2017; 12(9):1388-1397. DOI: 10.1016/j.jtho.2017.06.006. View

Mao C, Liao R, Chen Q . Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer. Br J Cancer. 2010; 102(5):940. PMC: 2833261. DOI: 10.1038/sj.bjc.6605575. View

Huang L, Fu L . Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015; 5(5):390-401. PMC: 4629442. DOI: 10.1016/j.apsb.2015.07.001. View

Wu S, Chang Y, Yu C, Yang P, Shih J . The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. Sci Rep. 2016; 6:35249. PMC: 5062358. DOI: 10.1038/srep35249. View

Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F . Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25(12):1545-52. DOI: 10.1200/JCO.2005.05.1474. View

Cheng Y, Murakami H, Yang P, He J, Nakagawa K, Kang J . Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. J Clin Oncol. 2016; 34(27):3258-66. DOI: 10.1200/JCO.2016.66.9218. View

Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View

Kobayashi S, Boggon T, Dayaram T, Janne P, Kocher O, Meyerson M . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. DOI: 10.1056/NEJMoa044238. View

Duan J, Xu J, Wang Z, Bai H, Cheng Y, An T . Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. J Thorac Oncol. 2020; 15(12):1857-1870. DOI: 10.1016/j.jtho.2020.08.020. View

10.

Li N, Wang B, Li J, Shao Y, Li M, Li J . Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer. Cancer. 2022; 128(4):708-718. DOI: 10.1002/cncr.33985. View

11.

Griesinger F, Korol E, Kayaniyil S, Varol N, Ebner T, Goring S . Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer. 2019; 135:196-204. DOI: 10.1016/j.lungcan.2019.07.010. View

12.

Deng L, Gao G, Deng H, Wang F, Wang Z, Yang Y . Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC. J Cancer Res Clin Oncol. 2019; 145(10):2613-2624. DOI: 10.1007/s00432-019-03001-2. View

13.

Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M . Impact of Mutations on Outcome in -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clin Cancer Res. 2016; 23(9):2195-2202. DOI: 10.1158/1078-0432.CCR-16-0966. View

14.

Scagliotti G, Ceppi P, Capelletto E, Novello S . Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009; 10 Suppl 1:S35-40. DOI: 10.3816/CLC.2009.s.006. View

15.

Gammelgaard K, Vad-Nielsen J, Clement M, Weiss S, Daugaard T, Dagnaes-Hansen F . Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC. Transl Oncol. 2018; 12(3):432-440. PMC: 6297127. DOI: 10.1016/j.tranon.2018.11.017. View

16.

Nardo G, Carlet J, Marra L, Bonanno L, Boscolo A, Dal Maso A . Detection of Low-Frequency Mutations in cfDNA From -Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. Front Oncol. 2021; 10:607840. PMC: 7844327. DOI: 10.3389/fonc.2020.607840. View

17.

Canale M, Petracci E, Delmonte A, Bronte G, Chiadini E, Ludovini V . Concomitant Mutation Confers Worse Prognosis in -Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. J Clin Med. 2020; 9(4). PMC: 7230306. DOI: 10.3390/jcm9041047. View

18.

Liu S, He Y, Jiang T, Ren S, Zhou F, Zhao C . EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. Lung Cancer. 2018; 120:82-87. DOI: 10.1016/j.lungcan.2018.04.004. View

19.

Li C, Zhang B, Guo J, Hu F, Nie W, Zheng X . Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR-Mutant Lung Adenocarcinoma. Target Oncol. 2019; 14(4):423-431. DOI: 10.1007/s11523-019-00649-1. View

20.

Lim Z, Ma P . Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019; 12(1):134. PMC: 6902404. DOI: 10.1186/s13045-019-0818-2. View